(Q73181530)
Statements
Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors (English)
V M Herben
J H Schellens
M Swart
G Gruia
L Vernillet
W W ten Bokkel Huinink